Back to top
more

Cogent Biosciences (COGT)

(Delayed Data from NSDQ)

$10.05 USD

10.05
779,262

-0.43 (-4.10%)

Updated Nov 7, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting

by Zacks Equity Research

Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.

Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Cogent Biosciences, Inc. (COGT) points to a 78.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Cogent Biosciences, Inc. (COGT) Is a Great Choice for "Trend" Investors, Here's Why

by Zacks Equity Research

Cogent Biosciences, Inc. (COGT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's What Could Help Cogent Biosciences, Inc. (COGT) Maintain Its Recent Price Strength

by Zacks Equity Research

Cogent Biosciences, Inc. (COGT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More

by Zacks Equity Research

Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.

Cogent (COGT) Surges on Robust Data from Mastocytosis Study

by Zacks Equity Research

Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.

    Company News for Jun 13, 2022

    by Zacks Equity Research

    Companies In The News Are: DOCU, COGT, BA, SFIX.

    Cogent Biosciences, Inc. (COGT) Reports Q4 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Cogent Biosciences, Inc. (COGT) delivered earnings and revenue surprises of -1910.00% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    New Strong Sell Stocks for November 18th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

    New Strong Sell Stocks for November 12th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

    Can the Rally in Cogint (COGT) Shares Continue?

    by Zacks Equity Research

    Cogint, Inc. (COGT) has been on the move lately as the stock has risen by 17.2% in the past four weeks, and it is currently trading well above its 20-Day SMA

      Should You Buy Cogint (COGT) Ahead of Earnings?

      by Zacks Equity Research

      Cogint (COGT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

        Cogint, Inc. (COGT) Jumps: Stock Rises 6.9%

        by Zacks Equity Research

        Cogint, Inc. (COGT) was a big mover last session, as the company saw its shares nearly 7% on the day amid huge volumes.

          Falling Earnings Estimates Signal Weakness Ahead for Cogint (COGT)

          by Zacks Equity Research

          It seems to be a wise decision for investors to drop Cogint (COGT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.

            Anupama Mukhopadhyay headshot

            Can IDI (COGT) Run Higher on Strong Earnings Estimate Revisions?

            by Anupama Mukhopadhyay

            On the back of solid estimate revisions, investors may definitely want to consider this Zacks Rank #2 IDI (COGT) stock to profit in the near future.

              Cogint (COGT): An Off-the-Radar Potential Winner

              by Zacks Equity Research

              Cogint (COGT) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

                Acxiom Teams Up with Verve to Boost Mobile-based Marketing

                by Zacks Equity Research

                Acxiom (ACXM), a formidable player in the field of marketing services and technology, has announced a partnership with Verve, for location-powered mobile marketing.